Interview with G.A.Efimov. T-cell Immunity is Much Better Protected against Viral Mutations than Humoral Immunity
- 作者: Efimov G.A1
-
隶属关系:
- National Medical Research Center for Hematology, Ministry of Health of the Russian Federation
- 期: 编号 5 (2021)
- 页面: 3-8
- 栏目: Articles
- URL: https://journals.eco-vector.com/0032-874X/article/view/631046
- DOI: https://doi.org/10.7868/S0032874X2105001X
- ID: 631046
如何引用文章
详细
In response to coronavirus infection, just as with any other infection, our body mobilizes two immune defense systems: antibodies and T-lymphocytes, or T-cells. The humoral response to SARS-CoV-2 infection (the production of antibodies that intercept the virus and prevent it from infecting the cell) has been well-studied; however T-cell response is not. Nevertheless, it is T-lymphocytes that not only detect and destroy infected cells, but also affect long-term immune memory. How is T-cell immunity tested? Are there any differences in its development in people who have had COVID-19 and those who have been vaccinated? Will vaccines created for the original SARS-CoV-2 protect against mutants? Grigorii Aleksandrovich Efimov, Candidate of Biological Sciences, Head of the Laboratory of Transplant Immunology at the National Medical Research Center for Hematology answers these and other questions.
作者简介
G. Efimov
National Medical Research Center for Hematology, Ministry of Health of the Russian FederationMoscow, Russia
参考
- Shomuradova A.S., Vagida M.S., Sheetikov S.A., Efimov G.A. SARS-CoV-2 epitopes are recognized by a public and diverse repertoire of human T cell receptors. Immunity. 2020; 53(6): 1245–1257. doi: 10.1016/j.immuni.2020.11.004.
- Tarke A., Sidney J., Methot N. et al. Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees. BioRxiv. 02.2021. doi: 10.1101/2021.02.27.433180.
- Saini S.K., Hersby D.S., Tamhane T. et al. SARS-CoV-2 genomewide T cell epitope mapping reveals immunodominance and substantial CD8+ T cell activation in COVID-19 patients. Sci. Immunol. 2021; 6(58): eabf7550. doi: 10.1126/sciimmunol.abf7550.
补充文件
